Skeletal metastasis in renal cell carcinoma: Current and future management options

2012 ◽  
Vol 38 (4) ◽  
pp. 284-291 ◽  
Author(s):  
Steven L. Wood ◽  
Janet E. Brown
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Skeletal Metastasis ◽  
Management Options ◽  
Future Management

scholarly journals Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Jawaher Ansari ◽  
Muhammad Ali ◽  
Ashraf Farrag ◽  
Arwa M. Ali ◽  
Abdulaziz Alhamad
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Pharmacokinetic Data ◽  
Management Options ◽  
Stage Renal Disease ◽  
End Stage

Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor antibody, is indicated for the treatment of patients with mRCC who have received prior antiangiogenic therapy. Given the above-mentioned uncertainties, clinicians may be reluctant to use nivolumab for this patient population, leading to potential denial of life-prolonging medications. We report the case of a 72-year-old gentleman with mRCC and ESRD on dialysis who received second-line nivolumab therapy and achieved an excellent symptomatic and radiological response, remaining progression-free for over 22 months. In addition, we have reviewed the pharmacokinetic data and published retrospective case studies to review the management options for patients with mRCC and ESRD on dialysis.

scholarly journals Skeletal metastasis in renal cell carcinoma: A review

2018 ◽  
Vol 27 ◽  
pp. 9-16 ◽  
Author(s):  
Masood Umer ◽  
Yasir Mohib ◽  
Muhammed Atif ◽  
Muhammad Nazim
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Skeletal Metastasis

scholarly journals Optimal Management of Localized Renal Cell Carcinoma: Surgery, Ablation, or Active Surveillance

2009 ◽  
Vol 7 (6) ◽  
pp. 635-643 ◽  
Author(s):  
David Y. T. Chen ◽  
Robert G. Uzzo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Negative Impact ◽  
Management Options ◽  
Alternative Interventions ◽  
History Of ◽  
Open Radical Nephrectomy ◽  
Localized Renal Cell Carcinoma

Radical nephrectomy is historically accepted as standard treatment for localized renal cell carcinoma (RCC). However, the presentation of RCC has changed dramatically over the past 3 decades. Newer alternative interventions aim to reduce the negative impact of open radical nephrectomy, with the natural history of RCC now better understood. This article discusses current surgical and management options for localized kidney cancer.

scholarly journals The Management of Spinal Metastases from Renal Cell Carcinoma

2009 ◽  
Vol 91 (8) ◽  
pp. 649-652 ◽  
Author(s):  
James Langdon ◽  
Adam Way ◽  
Samuel Heaton ◽  
Jason Bernard ◽  
Sean Molloy
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Treatment Options ◽  
Spinal Metastases ◽  
Cement Augmentation ◽  
Management Options ◽  
Current Management ◽  
Posterior Decompression ◽  
Primary Disease

INTRODUCTION Osseous metastases occur in 50% of patients with renal cell carcinoma; of these, 15% occur in the spine. The treatment options for spinal metastases secondary to renal cell carcinoma are limited. This paper considers the current management options available for spinal metastases secondary to renal cell carcinoma. PATIENTS AND METHODS A review of four patients with spinal metastases secondary to renal cell carcinoma. RESULTS The presentation of four cases highlighting the current management options for spinal metastases secondary to renal cell carcinoma. CONCLUSIONS Historically, spinal metastases from renal cell carcinoma have been poorly managed; however, as the treatment of the primary disease improves, better treatment of the secondary disease is needed. Cement augmentation, used alone for prophylactic stabilisation or in conjunction with a posterior decompression and fixation, provides a useful addition in the management of these patients optimising their chance to remain ambulant, continent, and pain-free.

Gastric and esophageal metastases in renal cell carcinoma: systematic review and management options

2014 ◽  
Vol 4 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Santiago Cabezas-Camarero ◽  
Javier Puente ◽  
Aránzazu Manzano ◽  
Eduardo Ayala ◽  
Héctor Callata ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Management Options

1253: Different Survival in PT3A Renal Cell Carcinoma with Sinus Fat Invasion or Perinephric Fat Invasion

2007 ◽  
Vol 177 (4S) ◽  
pp. 413-413
Author(s):  
Marco Roscigno ◽  
Roberto Bertini ◽  
Cesare Cozzarini ◽  
Alessandra Pasta ◽  
Mattia Sangalli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Perinephric Fat

1252: Relative Survival Following Treatment for Renal Cell Carcinoma (RCC)- A S.E.E.R. Analysis: Is Age Important?

2007 ◽  
Vol 177 (4S) ◽  
pp. 413-413
Author(s):  
Yu-Ning Wong ◽  
Brian L. Egleston ◽  
Ismail R. Saad ◽  
Robert G. Uzzo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Relative Survival
Sign in / Sign up

Export Citation Format

Share Document